Application of antibody-chemotherapy combination therapy to improve lung cancer survival rate
Release date: 2015-02-26 Recently, the famous international journal PNAS published a new study by American scientists. They found that the combination of antibody-chemotherapy can improve the survival rate of patients with non-small cell lung cancer. This effect may depend on the vascular function of the tumor during treatment. It is also proposed to use PIGF as a biomarker for detecting drug efficacy and VEGFR1 as a biomarker for resistance therapy. At present, the study found that the addition of anti-VEGF antibody to standard chemotherapy can improve survival rate, and it has been accepted as a treatment strategy for advanced non-small cell lung cancer. However, the specific mechanism by which anti-VEGF antibody therapy increases survival is still unclear. After treatment with bevacizumab alone and bevacizumab-carboplatin-paclitaxel in patients with advanced non-small cell lung cancer, the researchers performed dynamic CT-based vascular parameter analysis and plasma cytokine analysis in an attempt to find this response. Treatment and potential biomarkers against this treatment. The researchers found that anti-VEGF treatment leads to a sustained increase in plasma PIGF, so PIGF may be a potential pharmacodynamic marker. It has also been found that high levels of soluble VEGFR1 are associated with poor patient survival before the combination therapy, so VEGFR1 can be used as a marker of drug resistance. This study suggests that treatment with bevacizumab may be associated with improved patient survival, while tumor vasculature and blood are improved after treatment. The researchers hypothesized based on the findings that they suggested that excessive reduction in vascular permeability after bevacizumab treatment may have a negative impact on the combination of NSCLC patients. Based on this hypothesis, the researchers should conduct a further dose titration study of bevacizumab to examine the effect of this dose effect on tumor vasculature and treatment efficiency. Taken together, the article found that antibody-chemotherapy combination therapy to improve survival in patients with non-small cell lung cancer may depend on the vascular function of the tumor during treatment, and these correlation studies may be useful for selecting options that may benefit from combination therapy. Targeted treatment of NSCLC patients is of great significance. Source: Bio Valley Hydrophilic Intermittent Catheter Hydrophilic Catheter,Lofric Catheter Female,Hydrophilic Urinary Catheter,Lofric Single Use Urinary Catheter K-MED Co., Ltd. , https://www.kmedasia.com